Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $37.3M | $45.6M | $57.6M | $72.6M | $71.1M | $98.0M | $122M | $149M | $205M | $236M |
| Revenue growth | — | 22.3% | 26.2% | 26.0% | -2.0% | 37.9% | 24.7% | 21.6% | 37.6% | 15.4% |
| Gross profit | $26.4M | $34.5M | $42.7M | $54.6M | $55.0M | $73.4M | $90.7M | $111M | $149M | $173M |
| Gross margin | 70.7% | 75.5% | 74.2% | 75.3% | 77.4% | 74.9% | 74.1% | 74.8% | 72.6% | 73.1% |
| Operating income | -$6.13M | -$6.47M | -$9.55M | -$9.08M | -$26.8M | -$18.0M | -$25.4M | -$26.8M | -$35.0M | -$39.2M |
| Operating margin | -16.4% | -14.2% | -16.6% | -12.5% | -37.6% | -18.4% | -20.8% | -18.0% | -17.1% | -16.6% |
| Net income | -$6.57M | -$8.93M | -$12.0M | -$13.7M | -$32.9M | -$16.3M | $1.26M | -$21.0M | -$37.8M | -$39.6M |
| Net margin | -17.6% | -19.6% | -20.9% | -18.9% | -46.3% | -16.6% | 1.0% | -14.1% | -18.5% | -16.8% |
| EPS (diluted) | -$7.14 | -$5.86 | -$0.96 | -$0.94 | -$1.82 | -$0.84 | $0.06 | -$0.92 | -$1.64 | -$1.69 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$1.12M | -$7.22M | -$15.6M | -$17.8M | -$18.5M | -$13.1M | -$21.8M | -$27.0M | -$27.0M | -$4.85M |
| Capital expenditures | $4.35M | $5.21M | $5.25M | $11.8M | $10.5M | $8.10M | $10.0M | $16.9M | $14.3M | $11.1M |
| Free cash flow | -$5.47M | -$12.4M | -$20.8M | -$29.6M | -$29.0M | -$21.2M | -$31.8M | -$43.9M | -$41.3M | -$16.0M |
| Dividends paid | $0.00 | $5.96M | $0.00 | $0.00 | — | — | — | — | — | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $1.61M | $42.6M | $60.7M | $70.8M | $28.8M | $7.64M | $8.99M | $31.1M | $43.8M | $19.6M |
| Total assets | $30.7M | $82.3M | $112M | $182M | $320M | $304M | $428M | $439M | $473M | $509M |
| Total liabilities | $24.7M | $34.8M | $30.4M | $39.8M | $85.6M | $78.9M | $49.1M | $61.7M | $119M | $162M |
| Long-term debt | $17.4M | $25.3M | $21.2M | $26.1M | $1.04M | $907K | $763K | $9.91M | $73.0M | $99.8M |
| Shareholders' equity | -$65.3M | $47.5M | $81.7M | $142M | $235M | $225M | $379M | $377M | $355M | $347M |
| Retained earnings | -$78.1M | -$103M | -$115M | -$129M | -$162M | -$178M | -$177M | -$198M | -$236M | -$275M |
| Shares (wtd avg diluted) | 2.42M | 12.6M | 14.5M | 14.6M | 18.1M | 19.3M | 20.9M | 22.7M | 23.1M | 23.5M |
Every figure is extracted from ORTHOPEDIATRICS CORP’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.